In these two trial programs, tirzepatide in doses of 5 mg to 15 mg administered subcutaneously once weekly resulted in body weight reduction of up to 15% in participants with T2D and up to 21% in participants without T2D, despite comparable baseline bodyweight
The need for better breast cancer prevention strategies GLP-1 medications are highly effective at helping people lose weight, and maintaining a healthy weight has long been recommended as part of breast cancer prevention strategies because being overweight or obese, particularly after menopause, is a known risk factor for breast cancer
2 These outcomes suggest that Omadas program may support sustained weight loss beyond medication persistence alone
Association of dietary intakes of vitamin B12, vitamin B6, folate, and methionine with the risk of esophageal cancer: the Japan Public Health Center-based (JPHC) prospective study
Fried foods and very rich meals often trigger gastrointestinal symptoms and should be limited, especially early in treatment
